Serum levels of parathyroid hormone and markers of bone metabolism in patients with rheumatoid arthritis. Relationship to disease activity and glucocorticoid treatment

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in the context of rheumatoid arthritis in this clinical trial publication.

To evaluate the influence of inflammatory activity and glucocorticoid (GC) treatment on serum parathyroid hormone (s-PTH) and bone metabolism in patients with rheumatoid arthritis (RA).

Furthermore, in patients with active RA, to examine the PTH secretion and Ca2+ set point before and after treatment with GC.

Who Took Part

The abstract describes 95 patients taking part.

A range of biochemical markers of bone metabolism and calcium homeostasis were measured in 95 patients with definite RA stratified into groups according to disease activity and GC treatment.

In a subgroup of 12 patients with active disease, initiating slow-acting-anti-rheumatic-drugs (SAARDs) +/- GC, the PTH secretion and calcium set point were evaluated by use of the Cica clamp technique before and after 1 month of treatment.

How the Study Was Run

The methods mention a period of 1 month.

What Was Measured

PubMed files the paper under topics including Anti-Inflammatory Agents, Arthritis, Rheumatoid, Biomarkers, Bone and Bones, Cohort Studies, Cross-Sectional Studies and Glucocorticoids.

What This Means in Plain Language

This is a clinical trial of Parathyroid Hormone (PTH 1-84) in 95 patients in people with rheumatoid arthritis over 1 month.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Scandinavian journal of clinical and laboratory investigation), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Rheumatoid arthritis research.